NASDAQ: AVXL

Dr. Audrey Gabelle, MD, PhD

Scientific Advisor

Dr. Audrey Gabelle is a Professor of Neurology, MD, PhD, Neurologist and Doctor in Neurosciences at the Memory Resources Research Center, the Rare and Early Dementia Reference Center and the European Neurodegenerative Excellence Center of Montpellier University. Dr. Gabelle is also a researcher at the Montpellier Institute of Neurosciences and a member of the European Alzheimer’s Disease Consortium.

Professor Dr. Gabelle is an accomplished leader with 10+ years of experience driving innovation in addition to 10+ years in clinical Phase I–IV trials. She managed 400+ memory centers within the French network. She has a strong publication record with 200+ peer-reviewed scientific papers and is experienced in public-private partnerships and collaborations with pharmaceutical companies. She was a founding member of research projects at both the European and global level and works with international teams.

Professor Dr. Gabelle has expertise in diagnosis, predictive and prognostic biomarkers with the creation of the NeuroCognition biobank in 2007, which includes more than 35,000 samples with CSF, plasma proteomics profiles, and clinical follow-up data. She is involved in major cohorts, including the 3C Study, BALTAZAR, MEMENTO, MAPT, and EPAD, aimed at determining risk stratification and preventive strategies at early stages of neurodegenerative diseases.

You are about to leave our website

By clicking “Continue,” you acknowledge that you are leaving the Anavex Life Sciences website and will be redirected to a third-party website operated by NASDAQ or its affiliates.

Anavex Life Sciences does not own, control, maintain, or endorse the content on third-party websites and is not responsible for their accuracy, completeness, or reliability. Any information available through this link is provided by third parties and does not represent the views, opinions, forecasts, or predictions of Anavex Life Sciences or its management.

The linked content is provided for informational purposes only and does not constitute investment advice or an offer to buy or sell securities. Investors should rely on their own independent judgment and consult professional advisors before making any investment decisions.